Vioxx
(rofecoxib)ApprovedSmall molecule
Vioxx is one of 14 small molecule programs targeting Headache. It is currently in Approved.
3
Indications
12
Total Trials
0
Active Trials
13
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Sprain
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Keflex
Eli LillyApproved
Zyloprim
Jazz PharmaceuticalsApproved
Oruvail
WWyeth-Lederle Vaccines
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Tylenol
KKenvue Brands
Approved
Indocin
CCosette Pharmaceuticals, Inc.
Approved
Advil
KKenvue Brands
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Sprain1 trial
6 more indications
Advanced NSCLC1 trial
Third Molar1 trial
Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction
Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00026819·150 enrolled
Alzheimer's Disease1 trial
Regulatory
FDA Approval Timeline[4]
May 20, 1999
VIOXX
NDA NDA021052
May 20, 1999
VIOXX
NDA NDA021042
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rofecoxib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details